Medline Inc. MDLN R3KPHARMA
Company Overview
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
Why Investors Should Care
Revenue has grown at a 10.6% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $28.43B (+11.5% YoY); net profit $1.16B.
- Trailing 12 Months Year-on-year growth — revenue +11.6%, earnings +262.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.63% |
| 1 Year: | 11.60% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 262.00% |
Stock Price Performance
| 1 Year: | -15.39% |
| 6 Months: | -20.09% |
| 3 Months: | +2.63% |
| 1 Month: | -1.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)44.34 · Neutral
P/E of 43.36 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 30.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDLN Medline Inc. R3KPHARMA | 34.69 | 43.36 | $30.44B | 0.00% | 6.15% | 4.93% | 10.63% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 6.64B | 6.89B | 7.35B | 7.68B |
| Gross Profit | 1.82B | 1.91B | 1.84B | 2.21B |
| Operating Income | 571.00M | 642.00M | 422.00M | 395.00M |
| Net Income | 319.00M | 329.00M | - | - |
| Diluted EPS | - | - | 0.16 | 0.07 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 23.23B | 25.51B | 28.43B |
| Gross Profit | 5.88B | 6.98B | 7.52B |
| Operating Income | 1.25B | 2.15B | 2.21B |
| Net Income | - | - | 1.16B |
| Diluted EPS | - | - | -0.01 |
| R&D Expense | 60.00M | 67.00M | 80.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | - | 38.48B |
| Current Assets | - | - | 10.68B |
| Cash & Equivalents | - | - | 1.94B |
| Inventory | - | - | 4.77B |
| Receivables | - | - | 3.53B |
| Total Liabilities | - | - | 19.20B |
| Current Liabilities | - | - | 2.49B |
| Long Term Debt | - | - | 12.48B |
| Total Debt | - | - | 12.63B |
| Total Equity | 55.00M | 16.52B | 10.74B |
| Shares Outstanding | 799.80M | 812.00M | 812.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 1.69B | 1.77B | 1.74B |
| Investing Cash Flow | -312.00M | -1.49B | -474.00M |
| Financing Cash Flow | -191.00M | -1.61B | 399.00M |
| Capital Expenditure | -275.00M | -354.00M | -447.00M |
| Free Cash Flow | 1.41B | 1.42B | 1.30B |
| Share Buybacks | 0 | 20.00M | 33.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 25.3% | 27.3% | 26.4% |
| Operating Margin % | 5.4% | 8.4% | 7.8% |
| Net Margin % | - | - | 4.1% |
| ROE % | - | - | 10.8% |
| ROCE % | - | - | 6.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Carlyle Group Inc. | 21.32% | 187.08M | $5.92B |
| 2 | H&f Corporate Investors X, Ltd. | 8.08% | 70.87M | $2.24B |
| 3 | FMR, LLC | 5.35% | 46.96M | $1.49B |
| 4 | Capital Research Global Investors | 4.56% | 39.96M | $1.26B |
| 5 | Invesco Ltd. | 4.37% | 38.35M | $1.21B |
| 6 | Blackrock Inc. | 3.01% | 26.39M | $835.09M |
| 7 | Morgan Stanley | 2.46% | 21.61M | $683.60M |
| 8 | Lone Pine Capital Llc | 2.39% | 20.97M | $663.44M |
| 9 | Massachusetts Financial Services Co. | 2.27% | 19.89M | $629.28M |
| 10 | Vanguard Capital Management LLC | 2.03% | 17.82M | $563.70M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDLN
MDLN Stock Price and Chart — NASDAQ:MDLN - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBZc0VaYkN2cVIxRUhNTlNKXzlyUmZIQzFGXzBwbjkzOEdYSUdabm5Oek1NdmZyQWFTVklsa20zQU9aRzQ1UWo2OE41REE4c3ZRUW5RUzNUMXg4ZlBU?oc=5" target="_blank">MDLN Stock Price and Chart — NASDAQ:MDLN</a…
Artisan Sold Medline (MDLN) as Cost Pressures Delayed the Company’s Profit Recovery - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNTWhzbnNjVmNzbXhQWjVpSXdocm9MTXFBNFdKd1ZBemIxMzJkbDBINjRCZWZTM0dsUjlzNENIZWJGZHkxTWVObXl2N2NGMHdzVU1ESEVsbFh2V2pmenNsMzJDZUpkMi1NYU8xeVQzZ05PMU1rZnRMRnl2NGp3endVY2djOFNmNHc3Q3ZicD…
Nykredit A S Acquires New Holdings in Medline $MDLN - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPM2pacWJ2SVlUTU9ZY2FiTzJfdC1PM1pSMzJaZndQaUk4Y1hkRDN4TUdnU3pQR2FOUmN2dC1HeUs2X1BLbk5STmh4S0lpWTM0WklxQzhrcm0wWl9LR1FhQnRVdU5yTkpHZ0JpbTlCcDBfRGZwTjkxbUFvejR0MkJtV3UzMEFHbW9OdkFVVm…
(MDLN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOTldmMXhVOE9XOW9ZU3NWemt0MHUxM2thQjJHY2ttLUlaZzdtSlcwWDFxejl2NUpMeElwQ1oyR2J5NWd5Z2I4aVVqVExZcTh1cEtReUo3Sk9icG9UZWRIdUplQnhtVXVHMTlDOWRUNkdrZDJoSlN0ZVRYZHU5b1paUUxTNVEtUkxXUmM5WT…
Why Medline (MDLN) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFAyVXpmakdGNHVtX2JVODV0VFhCeGRRRXBlOVZ3MThoWDNYdjJ2Z0p6ZVlIc0ZycmY3NFlNVHVaX2RZdS1qcHgyTl9qZ2szd3NnUlpZOFFTZHRXNTdIbXBpMkhwUm1vdlBKbjl6b1B0YjIzX1BFamM5eA?oc=5" target="_blank">Why M…
Medline (MDLN) Stock Looks Below Fair Value Even as Earnings Look Fair - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOYXByNW1IdE9DZE16U1dKSWkwQTBiVzg4blhzQ09TR3ZyUC10eVZ4SHB0ZHhmeE9yOE5aVkZRb3pCSmRJLWlJZW1UUW1HVWFFUzJnOG1vN2djdm9YSFFaVmc3anlMbUcyUl8xMVJYMVNFdE1xQkVPS255Y2NteFNTdGEtaWR5N1lKMUI4eE…
MDLN — Frequently Asked Questions
What is the current share price of Medline Inc. (MDLN)?
As of 2026-09-19 21:16 PDT, Medline Inc. (MDLN) trades at $34.69 on NasdaqGS. Its 52-week range is $32.58 to $49.99.
What is the market capitalisation of MDLN?
Medline Inc. (MDLN) has a market capitalisation of $30.44B on NasdaqGS.
What is the P/E ratio of MDLN?
MDLN trades at a trailing price-to-earnings (P/E) ratio of 43.36. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.40.
What is the return on equity (ROE) of MDLN?
MDLN has a return on equity (ROE) of 4.93%. Its return on capital employed (ROCE) is 6.15%.
Is MDLN a good stock to buy?
This page provides a data-driven analysis of Medline Inc. (MDLN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.